An Update on Current Prenatal Testing Options: First Trimester and Noninvasive Prenatal Testing

Journal of Midwifery and Women's Health

Volumn 60, Issue 1, 2015, Pages 24-36

  Latendresse, Gwen ^a   Deneris, Angela ^a  

^a NONE

Author keywords

Prenatal care; Prenatal diagnosis; Prenatal genetic testing; Prenatal screening

Indexed keywords

ALPHA FETOPROTEIN; CELL FREE FETAL DNA; CHORIONIC GONADOTROPIN; DNA; ESTRADIOL; INHIBIN A; PREGNANCY ASSOCIATED PLASMA PROTEIN A; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; CHORION VILLUS SAMPLING; COMMUNICATION SKILL; DIAGNOSTIC ACCURACY; DIRECT TO CONSUMER TESTING; DOWN SYNDROME; FALSE POSITIVE RESULT; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; GENETIC COUNSELING; GENETIC PRIVACY; GENETIC SCREENING; HUMAN; KARYOTYPING; MATERNAL BLOOD; MEDICAL ETHICS; MICROARRAY ANALYSIS; NEURAL TUBE DEFECT; NON INVASIVE MEASUREMENT; NONINVASIVE PRENATAL TESTING; NUCHAL TRANSLUCENCY MEASUREMENT; PRENATAL DIAGNOSIS; PRENATAL SCREENING; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; SENSITIVITY AND SPECIFICITY; TRISOMY 13; TRISOMY 18; TRISOMY 21; FEMALE; HIGH RISK PREGNANCY; MASS SCREENING; PREGNANCY; PRENATAL CARE; PROCEDURES;

BIOMARKERS; DOWN SYNDROME; FEMALE; GENETIC TESTING; HUMANS; MASS SCREENING; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY, HIGH-RISK; PRENATAL CARE; PRENATAL DIAGNOSIS;

EID: 84923238136     PISSN: 15269523     EISSN: 15422011     Source Type: Journal    
DOI: 10.1111/jmwh.12228     Document Type: Article

References (47)

1. Norton ME. Genetic screening and counseling. Curr Opin Obstet Gynecol. 2008;20(2):157-163.
2. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol. 2007;109(1):217-227.
3. Fletcher R, Fletcher S, Fletcher G. Clinical Epidemiology: The Essentials. 5th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2014.
4. Wilson KL, Czerwinski JL, Hoskovec JM, et al. NSGC practice guideline: Prenatal screening and diagnostic testing options for chromosome aneuploidy. J Genet Couns. 2013;22(1):4-15.
5. Driscoll DA, Gross SJ. First trimester diagnosis and screening for fetal aneuploidy. Genet Med. 2008;10(1):73-75.
6. Chitayat D, Langlois S, Wilson RD. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can . 2011;33(7):736-750.
7. Tjoa ML, Cindrova-Davies T, Spasic-Boskovic O, Bianchi DW, Burton GJ. Trophoblastic oxidative stress and the release of cell-free feto-placental DNA. Am J Pathol. 2006;169(2):400-404.
8. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(5):890-901.
9. Swanson A, Sehnert AJ, Bhatt S. Non-invasive prenatal testing: technologies, clinical assays and implementation strategies for women's healthcare practitioners. Curr Genet Med Rep. 2013;1(2):113-121.
10. Gagnon A, Wilson RD, Allen VM, et al. Evaluation of prenatally diagnosed structural congenital anomalies. J Obstet Gynaecol Can. 2009;31(9):875-881, 882-879.
11. Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol. 2006;107(1):6-10.
12. Goldstein I, Weizman B, Nizar K, Weiner Z. The nuchal translucency examination leading to early diagnosis of structural fetal anomalies. Early Hum Dev. 2014;90(2):87-91.
13. Alldred S, Deeks J, Guo B, Neilson J, Alfirevic Z. Second trimester serum tests for Down's syndrome screening. Cochrane Database Syst Rev. 2012;(6):CD009925.
14. Karadzov-Orlic N, Egic A, Filimonovic D, et al. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks. Srp Arh Celok Lek. 2012;140(9-10):606-611.
15. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-487.
16. Ashoor G, Syngelaki A, Poon LC, Rezende JC, Nicolaides KH. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: Relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26-32.
17. Daley R, Hill M, Chitty LS. Non-invasive prenatal diagnosis: Progress and potential. Arch Dis Child Fetal Neonatal Ed. 2014. DOI: 10.1136/archdischild-2013-304828.
18. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 545: non-invasive prenatal testing for fetal aneuploidy. Obstet Gynecol. 2012;120(6):1532-1534.
19. Devers PL, Cronister A, Ormond KE, Facio F, Brasington CK, Flodman P. Noninvasive prenatal testing/noninvasive prenatal diagnosis: the position of the National Society of Genetic Counselors. J Genet Couns. 2013;22(3):291-295.
20. National Coalition for Health Professional Education in Genetics. Non-invasive prenatal testing (NIPT) factsheet. 2012; http://www.nchpeg.org/index.php?option=com_content&view=article&id=384&Itemid=255. Accessed June 17, -2014.
21. Hui L, Vaughan JI, Nelson M. Effect of labor on postpartum clearance of cell-free fetal DNA from the maternal circulation. Prenat Diagn. 2008;28(4):304-308.
22. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. J Matern Fetal Neonatal Med. 2013;26(12):1180-1185.
23. Hudecova I, Sahota D, Heung MM, et al. Maternal plasma fetal DNA fractions in pregnancies with low and high risks for fetal chromosomal aneuploidies. PLoS One. 2014;9(2):e88484.
24. Benn P, Cuckle H, Pergament E. Non-invasive prenatal testing for aneuploidy: current status and future prospects. Ultrasound Obstet Gynecol. 2013;42(1):15-33.
25. American Institute of Ultrasound in Medicine. AIUM practice guideline for the performance of obstetric ultrasound examinations. J Ultrasound Med. 2013;32(6):1083-1101.
26. Cocciolone R, Brameld K, O'Leary P, Haan E, Muller P, Shand K. Combining first and second trimester markers for Down syndrome screening: Think twice. Aust N Z J Obstet Gynaecol. 2008;48(5):492-500.
27. Pergament E, Pergament D. Reproductive decisions after fetal genetic counselling. Best Pract Res Clin Obstet Gynaecol. 2012;26(5):517-529.
28. Wapner RJ, Driscoll DA, Simpson JL. Integration of microarray technology into prenatal diagnosis: Counselling issues generated during the NICHD clinical trial. Prenat Diagn. 2012;32(4):396-400.
29. American College of Obstetricians and Gynecologists Committee on Genetics. Committee opinion on no. 581: the use of chromosomal microarray analysis in prenatal diagnosis. Obstet Gynecol. 2013;122(6):1374-1377.
30. Benn P, Chapman AR, Erickson K, et al. Obstetricians' and gynecologists' practice and opinions of expanded carrier testing and non-invasive prenatal testing. Prenat Diagn. 2013;34(2):145-152.
31. Audibert F, Wilson RD, Allen V, et al. Preimplantation genetic testing. J Obstet Gynaecol Can. 2009;31(8):761-775.
32. Vendrell X, Bautista-Llacer R. A methodological overview on molecular preimplantation genetic diagnosis and screening: A genomic future? Syst Biol Reprod Med. 2012;58(6):289-300.
33. Latendresse G. Genetics. In Brucker M, King T, eds. Varney's Midwifery. 5th ed. Burlington, MA: Jones & Bartlett Learning; 2013.
34. National Coalition for Health Professional Education in Genetics. Risk Assessment. Pregnancy & health profile 2014; http://www.nchpeg.org/index.php?option=com_content&view=article&id=411&Itemid=278. Accessed June 17, 2014, 2014.
35. National Coalition for Health Professional Education in Genetics. The pregnancy & health profile: A risk assessment & screening tool. 2014; http://www.nchpeg.org/index.php?option=com_content&view=article&id=410&Itemid=277. Accessed June 17, 2014.
36. March of Dimes. Family health history form. 2014; http://www.marchofdimes.com/glue/files/family-health-history-form.pdf. Accessed June 17, 2014.
37. Abrams DJ, Geier MR. A comparison of patient satisfaction with telehealth and on-site consultations: A pilot study for prenatal genetic counseling. J Genet Couns. 2006;15(3):199-205.
38. Arnold KM, Self ZB. Genetic screening and counseling: family medicine obstetrics. Prim Care. 2012;39(1):55-70.
39. Rothwell E, Cole E, Dyer J, Latendresse G. Prenatal genetic screening information during the new OB visit: Is one minute enough? Regional Women's Health & Midwifery Conference: American College of Nurse Midwives, Utah Affiliate; 2013.
40. The National Human Genome Research Institute. The ethical, legal and social implicaitons (ELSI) research program. 2013; http://www.genome.gov/ELSI/. Accessed June 17, 2014.
41. Bodurtha J, Strauss JF, 3rd. Genomics and perinatal care. N Engl J Med. 2012;366(1):64-73.
42. Su P. Direct-to-consumer genetic testing: A comprehensive view. Yale J Biol Med. 2013;86(3):359-365.
43. Leighton JW, Valverde K, Bernhardt BA. The general public's understanding and perception of direct-to-consumer genetic test results. Public Health Genomics. 2012;15(1):11-21.
44. Valles SA. Should direct-to-consumer personalized genomic medicine remain unregulated?: A rebuttal of the defenses. Perspect Biol Med. 2012;55(2):250-265.
45. American College of Medicine Genetics Board of Directors ACMG Statement on Direct-to-Consumer Genetic Testing. Rockville, MD: American College of Medical Genetics; 2008.
46. Clarke T, Begley S. FDA warns Google-backed 23andMe to halt sales of genetic tests. Reuters. November 25, 2013, 2013.
47. International Society of Genetic Genealogy. List of DNA Testing Companies. http://www.isogg.org/wiki/List_of_DNA_testing_companies. Accessed June 17, 2014.